



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

Art Unit: 1645

Applicants: M. El-Sherbeini et al.

Serial No.: 09/701,229 Case No.: 20193P

Filed: 8/23/2001

For: MURD PROTEIN AND GENE OF  
PSEUDOMONAS AERUGINOSA

Examiner:  
Virginia Allen Portner *hinda*  
*7/29/03*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313

ON THE DATE APPEARING BELOW.

**RESPONSE TO RESTRICTION REQUIREMENT**

BY: *[Signature]*

REGISTRATION NO.: *40,407*

DATE: *July 18, 2003*

Sir:

This is in response to the Office Action mailed June 18, 2003. No fee is believed to be due. However, the Commissioner is authorized to charge any required fees or credit overpayments to Deposit Account No. 13-2755. Applicant requests reconsideration and re-examination in view of the amendments and remarks presented herein.

**REMARKS**

The Examiner has requested restriction of Claims 1-14 into Groups I-V. Applicant provisionally elects to prosecute Group I, claims 1-7, with traverse.

The Examiner states that the invention lacks unity in light of prior art disclosing a natural MurD mutant of SEQ ID NO 2, produced by E.coli, etc., as cited in the International Search Report, October 21, 1999, and therefore the disclosed polynucleotide and polypeptide do not define a unifying special technical feature. (Action at page 2). Applicant respectfully traverses.


The Examiner's use of the terminology "natural MurD mutant" to state that a MurD gene from E. coli is a mutant of the MurD genes of Pseudomonas aeruginosa

claimed in this application is far outside the commonly accepted definition of "mutant." Indeed, Applicant is not aware of any use of the terms "mutant" or "natural mutant" to describe the relationship between related gene from different genera of bacteria. Such usage is believed to be wrong.

Therefore, the Examiner's position is wrong and the polynucleotides and polypeptides of this invention are a unifying special technical feature as between Groups I and II and the methods of using those sequences expressed in the claims of Group III.

Applicant respectfully requests withdrawal of the requirement for restriction as between Groups I - III, Claims 1-11.

Respectfully submitted,



Michael D. Yablonsky  
Reg. No. 40,407  
Attorney for Applicants  
Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-4678

Date: July 18, 2003